Review Article

Should We Monitor ScVO\textsubscript{2} in Critically Ill Patients?

Sophie Nebout\textsuperscript{1} and Romain Pirracchio\textsuperscript{2}

\textsuperscript{1} Department of Anesthesiology and Critical Care Medicine, Hospital Lariboisière 75475, Paris, France
\textsuperscript{2} Department of Anesthesiology and Critical Care Medicine, Hôpital Européen Georges Pompidou, Université Paris V Descartes, Sorbonne Paris Cité, 20 Rue Leblanc, 75015 Paris, France

Correspondence should be addressed to Romain Pirracchio, romainpirracchio@yahoo.fr

Received 17 May 2011; Revised 8 July 2011; Accepted 25 July 2011

1. Introduction

Hemodynamic monitoring has become a common practice in the intensive care unit. Besides blood pressure measurement, most industrial efforts have concentrated on providing devices for cardiac output monitoring. However, adequate adaptation of these macrohemodynamic parameters is somehow challenging. Indeed, as cardiac output is an adaptive parameter, it is always difficult to judge whether a given value at a given time for a given patient is appropriate or not. Similarly, which value should be considered an appropriate goal for blood pressure, considering regional perfusion specificities (e.g., autoregulation or flow/pressure dependency), patient’s age, history of hypertension, and so on. Therefore, considering that O\textsubscript{2} supply to the tissue is the basic objective, intensivists have been trying to find out an integrative parameter that would be more suitable to globally assess hemodynamic status of their patients. As a surrogate for evaluating O\textsubscript{2} demand/supply adequacy, central oxygen venous saturation (ScvO\textsubscript{2}) has become a popular parameter. As explained for the dummies, oxygen venous saturation is interpreted as a bank statement at the end of the month: “if the balance is negative, you can consider two explanations: you spend too much money or you earn not enough.” The aim of the present paper is precisely to critically analyze the physiological basements for such an interpretation, the data that support its use in clinical practice, and finally the limits that should be kept in mind while using such a parameter at the bedside.

2. Physiological Background

2.1. Normal Circulation Physiology. One of the main goals of blood circulation is to ensure oxygen supply to organs and tissues. The determinants of arterial oxygen delivery (DO\textsubscript{2}) are

(i) cardiac output (CO);
(ii) arterial content in oxygen (CaO\textsubscript{2}).

The arterial content in oxygen has 2 components.

(1) The main component is oxygen bound to hemoglobin (Hb).
(2) The secondary component is dissolved oxygen.

The first one depends on hemoglobin concentration, hemoglobin affinity for oxygen (which varies for Hb isotypes
and with environmental conditions such as temperature, pH, or 2.3 DPG concentrations), and, therefore, Hb oxygen saturation. The second component depends on arterial partial pressure of oxygen (PaO₂) and is considered as negligible because of the very solubility coefficient of oxygen in plasma. It is then possible to set the equations:

(i) \( \text{CaO}_2 = (\text{Hb} \times 1.34 \times \text{SaO}_2) + (0.003 \times \text{PaO}_2) \),

(ii) \( \text{DO}_2 = \text{CO} \times \text{CaO}_2 \).

By ignoring the dissolved oxygen component, we get

(i) \( \text{DO}_2 = \text{CO} \times 1.34 \times \text{SaO}_2 \).

Arterial blood is then deoxygenated in tissues. Tissue oxygen extraction depends on their demand but also on their ability for oxygen extraction. Therefore, after peripheral oxygen extraction, venous oxygen content depends on arterial content and tissue oxygen extraction.

2.2. Pathophysiology of Circulatory Failure. Shock is one of the leading causes of admission in the intensive care unit. It is usually defined as a mean arterial pressure (MAP) <60 mmHg or a systolic arterial pressure (SAP) <90 mmHg, or a decrease in SAP greater than 40 mmHg as compared to the usual SAP [1]. For many years, hemodynamic management has focused on “macrocirculatory” parameters such as blood pressure or cardiac output. Though the magnitude of macrocirculatory disorders is well known to be related to prognosis [2], its optimization seems mandatory [3] but insufficient [4]. Indeed, in septic shock patients, Sakr et al. observed that after 24 h hours of intensive care, the values of MAP, cardiac index (CI), and central venous pressure (CVP) did not discriminate survivors from nonsurvivors.

Hence, shock can be defined as a macrohemodynamic instability leading to an inappropriate oxygen supply/demand balance. Schematically, as represented in Figure 1, any fall in DO₂ is initially compensated by an increase in tissue oxygen extraction (EO₂), explaining that tissue VO₂ is initially maintained. However, when tissue oxygen extraction capacity is overtaken, oxygen consumption begins to fall and lactate concentration increases, indicating a switch of the cellular metabolism from aerobic glycolysis to cytoplasmic anaerobic glycolysis. This threshold immediately precedes the onset of clinical organ failures.

Considering such a pathophysiological scheme, hemodynamic support in shock should aim at correcting macrocirculatory but also microcirculatory parameters in order to avoid any local fall in O₂ supply below this crucial threshold. Therefore, a parameter such as venous oxygen saturation (SvO₂), that should reflect the inadequacy in oxygen supply, might be of great help.

2.3. Physiological Determinants for Venous Oxygen Saturation. Oxygen extraction in the tissues can be mathematically defined as follows:

(i) \( \text{EO}_2 = \text{CO} \times (\text{CaO}_2 - \text{CvO}_2) \),

(ii) \( \text{EO}_2 = \text{VO}_2/\text{DO}_2 \),

with \( \text{CvO}_2 \) being venous oxygen content and \( \text{VO}_2 \) being oxygen consumption.

Then, venous oxygen saturation can then be calculated using the following formula:

(i) \( \text{SvO}_2 = \text{SaO}_2 - (\text{VO}_2/(\text{CO} \times \text{Hb} \times 1.34)) \).

Hence, any decrease in venous oxygen saturation should be explained by

(i) a decrease in SaO₂;
(ii) a decrease in cardiac output;
(iii) a decrease in hemoglobin level;
(iv) an increase of oxygen consumption (VO₂).

Thus, providing that \( \text{SaO}_2 \), oxygen consumption, and haemoglobin level are in normal ranges, \( \text{SvO}_2 \) can be used as a surrogate for cardiac output.

Likewise, if

(i) \( \text{EO}_2 = \text{CO} \times (\text{CaO}_2 - \text{CvO}_2) \),
(ii) \( \text{EO}_2 = \text{VO}_2/\text{DO}_2 \),

then,

(i) \( \text{EO}_2 = (\text{SaO}_2 - \text{SvO}_2)/\text{SaO}_2 \).

Consequently, when \( \text{SaO}_2 = 100\% \), then \( \text{EO}_2 = 1 - \text{SvO}_2 \) and \( \text{SvO}_2 = 1 - \text{EO}_2 \).

Then, \( \text{SvO}_2 \) is also a good surrogate for \( \text{EO}_2 \).

In shock, decrease in tissue oxygen supply is mostly related to a decrease in tissue blood flow, would it be relative (as in distributive shocks) or real (as in hemorrhagic shock). The first recommended measure in international guidelines for shock resuscitation consists in optimizing cardiac output by repeated fluid challenges [6], in order to correct oxygen supply/demand imbalance. In this aspect, \( \text{SvO}_2 \) measurements could help guiding fluid challenges in shock patients.
3. SvO₂—ScvO₂: Is It the Same?

The reference technique to assess the adequacy of oxygen supply is the mixed venous oxygen saturation (SvO₂), provided by pulmonary artery catheter (a.k.a. Swan-Ganz catheter) [7]. However, limitations related to difficulties of insertion and placement, but also to potential complications related with such a catheter, lead to a substantial decrease in its use. In the meantime, industrials have developed regular central venous catheter coupled with a fiberoptic lumen for continuous haemoglobin saturation monitoring. Placed through a jugular of a subclavian vein, at the confluent of the superior vena cava and the right auricle, such catheters actually monitor the central venous oxygen saturation (ScvO₂) [8].

However, one should ask whether SvO₂ and ScvO₂ provide the same information. Actually, taken in pulmonary artery, SvO₂ is a surrogate for global tissue oxygenation, whereas ScvO₂ essentially reflects the oxygenation of the upper part of the body (head, neck upper limbs, and upper part of the trunk) and of a lower proportion of the lower part of the body (lower part of the trunk and lower limbs), depending on the exact position of the catheter’s extremity. Anyhow, ScvO₂ does not include venous blood coming from coronary sinus commonly located in the right auricle. Thus, taken at the confluent of the vena cava in the right auricle (i.e., upstream from the coronary sinus), ScvO₂ does not include myocardial oxygenation. On the contrary, SvO₂ concerns venous blood from pulmonary artery, that is, by definition, after the coronary venous sinus. Such a difference might highly impact the observed values, given that (1) venous blood from the coronary sinus, with a saturation of oxygen close to 40%, is the most deoxygenated venous blood of the body [9] and (2) that in critically ill patients, myocardial oxygen supply/demand imbalance is likely to occur.

4. ScvO₂: A Validated Monitoring Parameter

4.1. Experimental Validation. Many studies have compared the ScvO₂ and SvO₂ values in the same patients (Table 1). Most of them showed a good correlation between ScvO₂ and SvO₂ and a similar trend in the temporal evolution. In 1989, Reinhart et al. [10] reported, in a dog model, a correlation coefficient between ScvO₂ and SvO₂ of 0.96. In this study, the two values exhibited less than 5% difference in 77% of the cases. Later on, Reinhart et al. [11] confirmed their results in ICU patients: ScvO₂ and SvO₂ had similar evolution in 90% of the cases and had a correlation coefficient of 0.81 (P < 0.001). Similarly, Martin et al. [12] reported a parallel evolution of ScvO₂ and SvO₂ in 75% of the cases. Considering such results, it seems that ScvO₂ and especially its evolution over time could be used as an interesting surrogate for SvO₂ monitoring. However, the impact of ScvO₂ monitoring on the prognosis of critically ill patients remained to be demonstrated.

4.2. Clinical Validation. Some authors, therefore, focused on evaluating the connection between ScvO₂ and prognosis and especially the benefits turnover considering ScvO₂ optimization as a goal for resuscitation. Pearse et al. [23] observed in a cohort of 118 postoperative patients from major surgery that a decrease in ScvO₂ during the first 8 hours was associated with an increase in 28-day morbidity and mortality. Consistently, Futier et al. [24] showed in major abdominal surgery that a ScvO₂ < 70% was associated with postoperative complications. In addition, ScvO₂ seems to be a reliable and sensitive parameter to detect hemorrhage in trauma patients admitted to the Emergency Room [25], while other series suggest that ScvO₂ could be a prognosis marker in myocardial infarction [26], acute heart failure [27], as well as in severe sepsis patients [28].

But the great clinical advantage related to early ScvO₂ has been suggested by Rivers et al. [29]. Indeed, these authors reported that, in severe sepsis patients, an early and aggressive therapy that aimed at normalizing in the first hours the values of ScvO₂ MAP and CVP achieved a reduction in inhospital mortality from 46.5% to 30.5% (relative risk 0.58 (0.38–0.87), P = 0.009). These results were later confirmed by two large studies [30, 31] conducted, respectively, on 15,022 and 330 patients that both showed a mortality reduction related to the implementation of ScvO₂ as a resuscitation goal. Though Levy’s et al. study [30] failed to show any survival improvement specifically related to ScvO₂ implementation, the global target implementation did (lactate measure, blood culture before antibiotics, broad spectrum antibiotics, fluid and vasopressors, CVP > 8 mmHg, and ScvO₂ > 70%). This could be partly explained by the fact that, among those 6 resuscitation targets, ScvO₂ > 70% was the less commonly achieved, both after the first quarter of patients was included and after the final quarter of patients was included (resp., in 13.3% and 24.3% of the cases). Recently, Jones et al. [32] showed, in 300 septic shock patients, that the mortality of patients who benefited from a ScvO₂ goal-directed therapy was low (23% (17–30%)) and similar to those who were treated using a lactate clearance goal-directed therapy (17% (11–24%)).

ScvO₂ is considered as a suitable prognosis factor in many clinical situations in the critically ill patients. The Surviving Sepsis Campaign [33], gathering all European guidelines regarding severe sepsis and sepsis shock patients management, suggested including ScvO₂ as a goal parameter in the first 6 hours of management (ScvO₂ > 70%).

5. ScvO₂ Limits

5.1. Theoretical Limits. The first limit of using ScvO₂ refers to its ignorance of the coronary sinus venous blood saturation. As the extremity of the ScvO₂ catheter usually stands upstream from the joining point of coronary sinus in the right auricle, the ScvO₂ value does not take into account the myocardial oxygen supply/demand adequacy. As myocardial oxygen extraction is physiologically basically high, venous coronary blood is one of the most deoxygenated venous bloods [9] of the body. This explains that the value of mixed
venous blood saturation of oxygen (SvO₂), which actually takes into account venous coronary blood, is usually lower than the ScvO₂. Moreover, any major increase in myocardial oxygen consumption could lead to a critical myocardial oxygen extraction that would have no impact on ScvO₂ monitoring. Besides, ScvO₂, just as SvO₂, is a global oxygenation parameter. So any local change in tissue oxygenation is at risk of being “diluted” in the rest of venous blood and then becoming undetectable. Similarly, in the case of a drop in regional venous saturation responsible for a drop of ScvO₂, it would not be possible to assess the affected territory without further exploration. Then, theoretically, the distal extremity of the central venous catheter is supposed to be placed at the joining point of vena cava and the right auricle to enable a suitable assessment of tissue oxygenation of inferior and superior territories. However, checking the position of the catheter’s distal extremity with chest X-ray is not accurate enough. Moreover, as venous saturation from the superior vena cava is systematically lower than inferior vena cava, any variation in the position of the catheter’s tip could have a major influence on the measures and therefore lead to ScvO₂ misinterpretation. Ultimately, as previously reported, ScvO₂ depends on tissue oxygen extraction and hemoglobin affinity for oxygen. Experiments report that septic patients could suffer from a decrease in oxygen extraction capacity [34, 35], a rise in capillary shunt [34], as well as changes in hemoglobin affinity for oxygen [36]. All these changes may alter the theoretical relationship between SvcO₂, and cardiac output, such as ScvO₂ interpretation, to guide hemodynamic therapy becomes more complex.

5.2. Clinical Limits. First of all, one could argue that ScvO₂ measurement requires a central venous catheter, which is an invasive technique, exposing patients to complications such as infection or hemorrhage. However, central venous lines are often needed for critically patients and could therefore be used for ScvO₂ monitoring. However, in severe sepsis and septic shock, tissue hyperperfusion should lead to particularly low ScvO₂ values, as observed by Rivers et al. in the early stage of sepsis. However, after the first hours of resuscitation, this situation is rarely met [37], and ScvO₂ values tend to be paradoxically normal or even raised. This could be explained by the physiological modification induced by sepsis and previously described (decrease in tissue oxygen extraction capacity, rise of capillary shunt, and changes in hemoglobin affinity for oxygen). Consistently, in such situations, the agreement between SvO₂ and ScvO₂ seems much less satisfactory, especially in the context of septic shock [22, 38, 39]. Besides, ScvO₂ clinical validation is mainly based on one single study [29], which is a single centre study, and its results are still controversial. As a matter of fact, van Beest et al. [37], in a Dutch prospective multicenter study, reported that only 1% of the patients meeting the inclusion criteria required by Rivers et al. [29] had a ScvO₂ <50%. Ho et al. [40], in a retrospective study, as well as the ARISE group (Australian Resuscitation of Sepsis Evaluation), in a multicenter study [41], reported an in-hospital mortality of 26–28% in patients who did not benefit from an early goal-directed therapy but that met the inclusion criteria for Rivers’ trial. This mortality rate is much lower than the one observed by Rivers in his control group. Finally, the low CVP values (5-6 mmHg) observed by Rivers et al. suggest that their patients were probably highly hypovolemic.

5.3. Global versus Regional Circulation. If global hemodynamic optimization is considered as an essential prerequisite to ensure adequate tissue perfusion, it may not be always sufficient to avoid the development of organ failure. The poor accuracy for global oxygen venous saturation monitoring to detect changes in regional oxygenation has been well described in animal models [42–44]. For instance, Legrand et al. [42] recently showed in a rat model that LPS-induced endotoxemia could induce alterations in microvascular perfusion and oxygenation in the renal cortex in rats, which appeared to be only weakly dependent on systemic and renal macrohemodynamic alterations. Consistently, Vallet et al. [44] and Lagoa et al. [43] reported, in endotoxemic dogs, that after resuscitation skeletal VO₂ is maintained when blood flow within the gut is significantly disturbed with mucosal hypoxia. In human beings, as described by Sakr et al. [4], global hemodynamic parameters fail to discriminate...
survivors from nonsurvivors after 24 hours of intensive care in septic shock patients. One illustrative example is the lack of accuracy of global SvO2 to detect cerebral venous desaturations [45]. In this perspective, global ScvO2 might face some limitations with respect to local inadequacy in the DO2/VO2 balance. Indeed, local SvO2 might not be detected by global oxygen saturation monitoring, the signal being diluted among a global normally saturated venous blood. Therefore, regional SvO2 could be an interesting supplementary target parameter. However, while regional SVO2 monitoring might be feasible at the bedside for some organ, such as jugular venous oxygen monitoring [46–48], it is much more difficult for others such as the kidney or the gut, for example. In such situation, some alternative parameters for regional monitoring could be of interest.

6. Candidate Parameter to Reflect Regional Inadequate Oxygen Supply

As for now, no biological or technical parameter has been proved to directly reflect regional oxygen supply inadequacy. Nevertheless, some parameters appear to be good surrogate candidate, such as tissue oxygen saturation (StO2) and regional carbon dioxide partial pressure (pCO2).

6.1. Tissue Oxygen Saturation (StO2). StO2 can be estimated by near-infrared spectroscopy (NIRS) using the differential absorption properties of oxygenated and deoxygenated hemoglobin. Near-infrared light (wave length 680–800 nm) easily crosses biological tissue and is only absorbed by hemoglobin, myoglobin, and oxidized cytochrome, but the contribution of myoglobin and oxidized cytochrome in light absorption is very low [49, 50]. Light tissue penetration is dependant on the space between the illumination fiber and the detection fiber. With a 25 mm space, 95% of the light signals detected come from a 0–23 mm depth.

The steady StO2 value is a reflection of oxygen saturation of the haemoglobin present in the tissue volume crossed by the near-infrared light, containing a mix of arteriolar, capillary, and venous blood. It is then a complicated integrative parameter, but it has been shown to be correlated to the microcirculation state and is therefore considered as an acceptable parameter for tissue perfusion [51].

During shock from various origins, the relationship between StO2 values at the forearm and the prognosis has been extensively studied during the past decade [52–55]. During shock states, as StO2 drops correlate with fall in central venous, mixed venous oxygen saturation, or oxygen delivery [56–59], StO2 seems to be a good marker of regional DO2/VO2 imbalance, with the advantage of being applicable to different regional territories such as the brain [60], the liver [61], or the muscle [62], for example. However, this technique suffers some limitations, the major one being its poor sensitivity to rule out tissue hypoperfusion [55]. In order to improve its sensitivity, vascular occlusion tests (transient upper arm arterial occlusion with a pneumatic cuff) have been proposed [63]. By continuously monitoring StO2 during the test, a pattern curve is obtained with an initial decrease of StO2 during occlusion, followed after cuff deflation by an increase of StO2 usually transiently reaching higher values than baseline (hyperemic response) before returning to baseline. The slope of the decreasing part of the curve is the StO2 desaturation rate and is correlated to the tissue oxygen consumption, whereas the slope of the increasing part of the curve is the StO2 recovery rate and is correlated to the quality of the microvascular bedside [64].

6.2. Carbon Dioxide Partial Pressure. Regional capnography relies on the principle that cellular oxygen consumption through oxidative phosphorylation produces proportional amount of carbon dioxide. In this perspective, any decrease in blood flow would result in a CO2 accumulation detected by a capnograph. Tissue pCO2 could then be used as a surrogate for regional blood flow and oxygen consumption combined [65]. However, regional pCO2 is difficult to interpret, because CO2 production also depends on cellular metabolism level and arterial glucose concentration. This probably explains the fact that, despite appealing, this parameter is still rarely used in clinical practice.

7. Conclusion

In conclusion, ScvO2 measurement seems to be an interesting tool, especially in the early phase of shock to guide fluid management and blood transfusion or inotropic support. Nevertheless, a large knowledge of its determinants and the physiology of circulation seem to be essential to ensure a reliable interpretation in clinical practice. When ScvO2 is low, it reflects an adaptive mechanism to an unsuitable supply in oxygen and should lead doctors to understand the reasons for it and to propose an appropriate optimization strategy. As well, in clinical situations such as septic shock, after the first hours of management, a “normal” or even a high ScvO2 can be falsely reassuring.

Conflict of Interests

The author declares that there is no conflict of interests.

References

[1] M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference,” Critical Care Medicine, vol. 31, no. 4, pp. 1250–1256, 2003.
[2] J. Vallés, J. Rello, A. Ochagavia, J. Garnacho, and M. A. Alcala, “Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival,” Chest, vol. 123, no. 5, pp. 1615–1624, 2003.
[3] M. Antonelli, M. Levy, P. J. Andrews et al., “Hemodynamic monitoring in shock and implications for management: International Consensus Conference, Paris, France, 27-28 April 2006,” Intensive Care Medicine, vol. 33, no. 4, pp. 575–590, 2007.
[4] Y. Sakr, M. J. Dubois, D. De Backer, J. Creteur, and J. L. Vincent, “Persistent-microcirculatory alterations are associated
with organ failure and death in patients with septic shock,” *Critical Care Medicine*, vol. 32, no. 9, pp. 1825–1831, 2004.

[5] J. L. Vincent and D. De Backer, “Oxygen transport—the oxygen delivery controversy,” *Intensive Care Medicine*, vol. 30, no. 11, pp. 1990–1996, 2004.

[6] J. L. Vincent and M. H. Weil, “Fluid challenge revisited,” *Critical Care Medicine*, vol. 34, no. 5, pp. 1333–1337, 2006.

[7] K. Reinhart and F. Bloos, “The value of venous oximetry,” *Current Opinion in Critical Care*, vol. 11, no. 3, pp. 259–263, 2005.

[8] M. M. Scheinman, M. A. Brown, and E. Rapaport, “Critical assessment of use of central venous oxygen saturation as a mirror of mixed venous oxygen in severely ill cardiac patients,” *Circulation*, vol. 40, no. 2, pp. 165–172, 1969.

[9] T. Miyairi, T. Miwa, T. Takayama, K. Ka, and K. Itoh, “Continuous monitoring of coronary sinus oxygen saturation during warm heart surgery,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 108, no. 4, pp. 795–796, 1994.

[10] K. Reinhart, T. Rudolph, D. L. Bredle, L. Hannemann, and S. M. Cain, “Comparison of central-venous to mixed-venous oxygen saturation during changes in oxygen supply/demand,” *Chest*, vol. 95, no. 6, pp. 1216–1221, 1989.

[11] K. Reinhart, H. J. Kuhn, C. Hartog, and D. L. Bredle, “Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill,” *Intensive Care Medicine*, vol. 30, no. 8, pp. 1572–1578, 2004.

[12] C. Martin, J. P. Auffray, C. Badetti, G. Perrin, L. Papazian, and F. Gouin, “Monitoring of central venous oxygen saturation versus mixed venous oxygen saturation in critically ill patients,” *Intensive Care Medicine*, vol. 18, no. 2, pp. 101–104, 1992.

[13] J. Tahvanainen, O. Meretoja, and P. Nikki, “Can central venous blood replace mixed venous blood samples?” *Critical Care Medicine*, vol. 10, no. 11, pp. 758–761, 1982.

[14] M. Wendt, T. Hachenberg, A. Albert, and R. Janzen, “Mixed venous versus central venous oxygen saturation in intensive medicine,” *Anaesth Intensivther Notfallmed*, vol. 25, no. 1, pp. 102–106, 1990.

[15] C. H. Kong, F. D. Thompson, and F. J. Imms, “Cardiac output and oxygen uptake in patients with renal failure,” *Clinical Science*, vol. 78, no. 6, pp. 591–596, 1990.

[16] J. C. Berridge, “Influence of cardiac output on the correlation between mixed venous and central venous oxygen saturation,” *British Journal of Anaesthesia*, vol. 69, no. 4, pp. 409–410, 1992.

[17] A. Herrera, A. Pajuelo, M. J. Morano, M. P. Ureta, J. Gutierrez-Garcia, and M. de las Mulas, “Comparison of oxygen saturations in mixed venous and central blood during thoracic anaesthesia with selective single-lung ventilation,” *Revista Española de Anestesiología y Reanimación*, vol. 40, no. 6, pp. 349–353, 1993.

[18] M. Pieri, L. S. Brandi, R. Bertolini, M. Calafà, and F. Giunta, “Comparison of bench central and mixed pulmonary venous oxygen saturation in critically ill postsurgical patients,” *Minerva Anestesiologica*, vol. 61, no. 7-8, pp. 285–291, 1995.

[19] C. Ladakis, P. Myrianthefs, A. Karabinis et al., “Central venous and mixed venous oxygen saturation in critically ill patients,” *Respiration*, vol. 68, no. 3, pp. 279–285, 2001.

[20] L. S. Chawla, H. Zia, G. Gutierrez, N. M. Katz, M. G. Seneff, and M. Shah, “Lack of equivalence between central and mixed venous oxygen saturation,” *Chest*, vol. 126, no. 6, pp. 1891–1896, 2004.

[21] M. H. Dueck, M. Klimek, S. Appenrodt, C. Weigand, and U. Boerner, “Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions,” *Anesthesiology*, vol. 103, no. 2, pp. 249–257, 2005.

[22] K. M. Ho, R. Harding, J. Chamberlain, and M. Bulsara, “A comparison of central and mixed venous oxygen saturation in circulatory failure,” *Journal of Cardiothoracic and Vascular Anesthesia*, vol. 24, no. 3, pp. 434–439, 2010.

[23] R. Pearse, D. Dawson, J. Fawcett, A. Rhodes, R. M. Grounds, and E. D. Bennett, “Changes in central venous saturation after major surgery, and association with outcome,” *Critical Care*, vol. 9, no. 6, pp. R694–R699, 2005.

[24] E. Futier, E. Robin, M. Jabaoud et al., “Central venous O2 saturation and venous-to-arterial CO2 difference as complementary tools for goal-directed therapy during high-risk surgery,” *Critical Care*, vol. 14, no. 5, article R193, 2010.

[25] T. M. Scalet, R. W. Hartnett, A. O. Duncan et al., “Central venous oxygen saturation: a useful clinical tool in trauma patients,” *The Journal of Trauma*, vol. 30, no. 12, pp. 1539–1543, 1990.

[26] A. M. Hutter Jr. and A. J. Moss, “Central venous oxygen saturations: value of serial determinations in patients with acute myocardial infarction,” *The Journal of the American Medical Association*, vol. 212, no. 2, pp. 299–303, 1970.

[27] D. S. Ander, M. Jaggi, E. Rivers et al., “Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department,” *The American Journal of Cardiology*, vol. 82, no. 7, pp. 888–891, 1998.

[28] M. Y. Rady, E. P. Rivers, G. B. Martin, H. Smithline, T. Appelton, and R. M. Nowak, “Continuous central venous oximetry and shock index in the emergency department: use in the evaluation of clinical shock,” *American Journal of Emergency Medicine*, vol. 10, no. 6, pp. 538–541, 1992.

[29] E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” *The New England Journal of Medicine*, vol. 345, no. 19, pp. 1368–1377, 2001.

[30] M. M. Levy, R. P. Dellinger, S. R. Townsend et al., “The surviving sepsis campaign: results of an international guideline-based performance improvement program targeting severe sepsis,” *Intensive Care Medicine*, vol. 36, no. 2, pp. 222–231, 2010.

[31] H. B. Nguyen, S. W. Corbett, R. Steele et al., “Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality,” *Critical Care Medicine*, vol. 35, no. 4, pp. 1105–1112, 2007.

[32] A. E. Jones, N. I. Shapiro, S. Trzcziak, R. C. Arnold, H. A. Claremont, and J. A. Kline, “Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial,” *The Journal of the American Medical Association*, vol. 303, no. 8, pp. 739–746, 2010.

[33] R. P. Dellinger, M. M. Levy, J. M. Carlet et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008,” *Critical Care Medicine*, vol. 36, no. 1, pp. 296–327, 2008.

[34] P. W. G. Elbers and C. Ince, “Bench-to-bedside review: mechanisms of critical illness—classifying microcirculatory flow abnormalities in distributive shock,” *Critical Care*, vol. 10, no. 4, article 221, 2006.

[35] R. J. Levy and C. S. Deutschman, “Cytochrome c oxidase dysfunction in sepsis,” *Critical Care Medicine*, vol. 35, no. 9, pp. 546–5475, 2007.

[36] J. J. Lebot, C. Elarby, J. J. Vallon, and J. Motin, “Oxygen-haemoglobin dissociation curve and 2,3-diphosphoglycerate
in septic shock,” *Annales Francaises d’Anesthésie et de Réanimation*, vol. 3, no. 2, pp. 85–89, 1984.

[37] P. A. van Beest, J. J. Hofstra, M. J. Schultz, C. E. Boerma, P. E. Spronk, and M. A. Kuiper, “The incidence of low venous oxygen saturation on admission to the intensive care unit: a multi-center observational study in The Netherlands,” *Critical Care*, vol. 12, no. 2, article R33, 2008.

[38] P. Kopterides, S. Bonovas, I. Mavrou, L. Bolinger, H. Li, K. Kendrick, B. Chance, and J. R. Wilson, “Validation of near-infrared spectroscopy in humans,” *Journal of Applied Physiology*, vol. 77, no. 6, pp. 2740–2747, 1994.

[39] M. Varpula, S. Karlsson, E. Ruokonen, and V. Pettilä, “Mixed venous oxygen saturation cannot be estimated by central venous oxygen saturation in septic shock,” *Intensive Care Medicine*, vol. 32, no. 9, pp. 1336–1343, 2006.

[40] B. C. H. Ho, R. Bellomo, F. McGain et al., “The incidence and outcome of septic shock patients in the absence of early-goal directed therapy,” *Critical Care*, vol. 10, no. 3, article R80, 2006.

[41] “The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand,” *Critical Care and Resuscitation*, vol. 9, no. 1, pp. 8–18, 2007.

[42] M. Legrand, R. Bezemer, A. Kandil, C. Demirci, D. Payen, and C. Ince, “The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats,” *Journal of Intensive Care Medicine*, vol. 37, no. 9, pp. 1534–1542, 2011.

[43] C. E. Lagoa, L. F. de Figueiredo, R. J. Cruz, E. Silva, and M. Rocha e Silva, “Effects of volume resuscitation on splanchnic perfusion in canine model of severe sepsis induced by live *Escherichia coli* infusion,” *Critical Care*, vol. 8, no. 4, pp. R221–R228, 2004.

[44] B. Vallet, N. Lund, S. E. Curtis, D. Kelly, and S. M. Cain, “Gut and muscle tissue PO2 in endotoxemic dogs during shock and resuscitation,” *Journal of Applied Physiology*, vol. 76, no. 2, pp. 793–800, 1994.

[45] N. Nagdyman, T. Fleck, S. Barth, E. Nahum, P. W. Skippen, R. E. Gagnon, A. J. Macnab, and E. D. Skarsgard, “Correlation of transcutaneous hepatic near-infrared spectroscopy readings with liver surface readings and perfusion parameters in a piglet endotoxemic shock model,” *Liver International*, vol. 26, no. 10, pp. 1277–1282, 2006.

[46] M. Girardis, L. Rinaldi, S. Busani, I. Flore, S. Mauro, and A. Pasetto, “Muscle perfusion and oxygen consumption by near-infrared spectroscopy in critically ill patients,” *Intensive Care Medicine*, vol. 35, no. 5, pp. 1106–1109, 2009.

[47] J. Creteur, T. Carollo, G. Soldati, G. Buchele, D. De Backer, and J. L. Vincent, “The prognostic value of muscle StO2 in septic patients,” *Intensive Care Medicine*, vol. 33, no. 9, pp. 1549–1556, 2007.

[48] J. M. Murkin and M. Arango, “Near-infrared spectroscopy as an index of brain and tissue oxygenation,” *British Journal of Anaesthesia*, vol. 103, supplement 1, pp. 13–113, 2009.

[49] E. Nahum, P. W. Skippen, R. E. Gagnon, A. J. Macnab, and E. D. Skarsgard, “Correlation of transcutaneous hepatic near-infrared spectroscopy readings with liver surface readings and perfusion parameters in a piglet endotoxemic shock model,” *Liver International*, vol. 26, no. 10, pp. 1277–1282, 2006.

[50] J. Creteur, T. Carollo, G. Soldati, G. Buchele, D. De Backer, and J. L. Vincent, “The prognostic value of muscle StO2 in septic patients,” *Intensive Care Medicine*, vol. 33, no. 9, pp. 1549–1556, 2007.

[51] M. O. Gayle, T. C. Frewen, R. F. Armstrong et al., “Jugular venous bulb catheterization in infants and children,” *Critical Care Medicine*, vol. 17, no. 5, pp. 385–388, 1989.

[52] E. L. Gibbs, W. G. Lennox, L. E. Nims, and F. A. Gibbs, “Arterial and cerebral venous blood: arterial-venous differences in man,” *The Journal of Biological Chemistry*, vol. 144, no. 2, pp. 325–332, 1942.

[53] R. Boushel and C. A. Plantadosi, “Near-infrared spectroscopy for monitoring muscle oxygenation,” *Acta Physiologica Scandinavica*, vol. 168, no. 4, pp. 615–622, 2000.

[54] D. M. Mancini, L. Bolinger, H. Li, K. Kendrick, B. Chance, and J. R. Wilson, “Validation of near-infrared spectroscopy in humans,” *Journal of Applied Physiology*, vol. 77, no. 6, pp. 2740–2747, 1994.

[55] M. Podbregar and H. Mozina, “Skeletal muscle oxygen saturation does not estimate mixed venous oxygen saturation in patients with severe left heart failure and additional severe sepsis or septic shock,” *Critical Care*, vol. 11, no. 1, article R6, 2007.

[56] S. M. Cohn, A. B. Nathens, F. A. Moore et al., “Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation,” *The Journal of Trauma*, vol. 62, no. 1, pp. 44–54, 2007.

[57] J. Creteur, T. Carollo, G. Soldati, G. Buchele, D. De Backer, and J. L. Vincent, “The prognostic value of muscle StO2 in septic patients,” *Intensive Care Medicine*, vol. 33, no. 9, pp. 1549–1556, 2007.

[58] M. Leone, S. Blidi, F. Antonini et al., “Oxygen tissue saturation is lower in nonsurvivors than in survivors after early resuscitation of septic shock,” *Anesthesiology*, vol. 111, no. 2, pp. 366–371, 2009.

[59] A. Rodriguez, T. Lisboa, I. Martin-Loeches et al., “Mortality and regional oxygen saturation index in septic shock patients: a pilot study,” *The Journal of Trauma*, vol. 70, no. 5, pp. 1145–1152, 2011.

[60] L. Heyer, A. Mebazaa, E. Gayat et al., “Cardiac troponin and skeletal muscle oxygenation in severe post-partum haemorhage,” *Critical Care*, vol. 13, supplement 5, article S8, 2009.

[61] J. Mesquida, G. Gruitmoner, M. L. Martinez et al., “Thermal oxygen saturation (StO2) and invasive oxygen delivery measurements in critically ill patients in early septic shock,” *Shock*, vol. 35, no. 5, pp. 456–459, 2011.

[62] J. Mesquida, J. Masip, G. Gili, A. Artigas, and F. Baigorri, “Thermal oxygen saturation measured by near infrared spectroscopy as a noninvasive predictor of low central venous oxygen saturation in septic patients,” *Intensive Care Medicine*, vol. 35, no. 6, pp. 1106–1109, 2009.

[63] K. E. Mulier, D. E. Skarda, J. H. Taylor et al., “Near-infrared spectroscopy in patients with severe sepsis: correlation with invasive hemodynamic measurements,” *Surgical Infections*, vol. 9, no. 5, pp. 515–519, 2008.

[64] J. M. Murkin and M. Arango, “Near-infrared spectroscopy as an index of brain and tissue oxygenation,” *British Journal of Anaesthesia*, vol. 103, supplement 1, pp. 13–113, 2009.

[65] E. Nahum, P. W. Skippen, R. E. Gagnon, A. J. Macnab, and E. D. Skarsgard, “Correlation of transcutaneous hepatic near-infrared spectroscopy readings with liver surface readings and perfusion parameters in a piglet endotoxemic shock model,” *Liver International*, vol. 26, no. 10, pp. 1277–1282, 2006.

[66] M. Girardis, L. Rinaldi, S. Busani, I. Flore, S. Mauro, and A. Pasetto, “Muscle perfusion and oxygen consumption by near-infrared spectroscopy in septic shock and non-septic shock patients,” *Intensive Care Medicine*, vol. 29, no. 7, pp. 1173–1176, 2003.

[67] C. Mayeur, S. Campard, C. Richard, and J. L. Teboul, “Comparison of four different vascular occlusion tests for assessing reactive hyperemia using near-infrared spectroscopy,” *Critical Care Medicine*, vol. 39, no. 4, pp. 695–701, 2011.

[68] A. Lima, J. van Bommel, K. Sikorska et al., “The relation of near-infrared spectroscopy with changes in peripheral circulation in critically ill patients,” *Critical Care Medicine*, vol. 39, no. 7, pp. 1649–1654, 2011.

[69] F. Vallée, J. Mateo, G. Dubreuil et al., “Cutaneous ear lobe PCO2 at 37°C to evaluate microperfusion in patients with septic shock,” *Chest*, vol. 138, no. 5, pp. 1062–1070, 2010.